Bayer submits aflibercept 8 mg for regulatory approval in two major retinal eye diseases in the EU

news image





10:59 AM


Not intended for U.S. and UK Media


Filing for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of clinical trials, PULSAR and PHOTON / In both trials, aflibercept 8 mg demonstrated unprecedented durability results with treatment intervals of up to 16 weeks, with comparable visual acuity as well as rapid and resilient fluid control to the comparator EyleaTM (aflibercept 2 mg) through to week 48 / Safety of aflibercept 8 mg was consistent with the safety profile of Eylea (aflibercept 2 mg) / Extended treatment intervals with less injections into the eye in nAMD and DME meet an important patient need

Read More